Shukra Pharmaceuticals approves name change to Shukra Medtech
Shukra Pharmaceuticals Limited board approved renaming the firm to Shukra Medtech Limited and expanding its main objects to include medical technology development and manufacturing. The move, approved on August 14, 2026, requires shareholder and regulatory approvals under the Companies Act, 2013 and SEBI regulations. This strategic shift aims to broaden the company's identity beyond pharmaceuticals into the wider healthcare ecosystem.
*this image is generated using AI for illustrative purposes only.
Shukra Pharmaceuticals Limited has moved to diversify its business scope by approving a change in its corporate name and an expansion of its operational mandate into the medical technology sector. The Board of Directors, at a meeting held on August 14, 2026, sanctioned the proposal to rename the entity from "Shukra Pharmaceuticals Limited" to "Shukra Medtech Limited" or such other name as approved by the Registrar of Companies.
Strategic Expansion into MedTech
The board also approved alterations to the Main Objects Clause of the Memorandum of Association. This expansion enables the company to undertake activities in the field of Medical Technology (MedTech), including:
- Development, manufacturing, processing, and designing
- Research and development
- Distribution, marketing, and trading
- Related activities in medical technology products, devices, equipment, systems, and solutions
These activities will be conducted subject to applicable laws and regulatory approvals. The company stated that this strategic shift is intended to provide a broader corporate identity and allow it to explore business opportunities in the medical technology sector alongside its existing pharmaceutical and healthcare-related activities.
Regulatory Approvals Required
The proposed alteration of the Memorandum of Association and the change of name are subject to several statutory requirements. The proposals must receive approval from the shareholders of the company. Additionally, the company must obtain necessary permissions, sanctions, and filings under:
- The Companies Act, 2013
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Other applicable laws and regulations
Shivkant Dhakad, Company Secretary, confirmed the board's decision. The company indicated it would make further disclosures regarding the process for obtaining requisite approvals as and when applicable. The initiative is described as part of the company's broader strategy to expand its presence across the healthcare and medical technology ecosystem for sustainable long-term growth.
Historical Stock Returns for Shukra Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
What specific MedTech product segments or technologies is Shukra prioritizing for its initial expansion efforts?
How might the shift to a MedTech-focused identity impact Shukra's valuation multiples compared to traditional pharmaceutical peers?
Will Shukra pursue organic growth through internal R&D or consider strategic acquisitions to accelerate its entry into the medical device market?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
